TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research In Vitro TMX-201 is more potent cytokine inducer than Imiquimod in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg . TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects . TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TLR7
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
TMX-201
CAS number：1149339-78-5 molecular formula：C57H93N6O12P
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1149339-78-5 | molecular formula | C57H93N6O12P |
| molecular weight | 1085.36 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
